https://scholars.lib.ntu.edu.tw/handle/123456789/535399
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Simon J. | en-US |
dc.contributor.author | HSIN-YUN SUN | en-US |
dc.contributor.author | Leong H.N. | en-US |
dc.contributor.author | Barez M.Y.C. | en-US |
dc.contributor.author | Huang P.-Y. | en-US |
dc.contributor.author | Talwar D. | en-US |
dc.contributor.author | Wang J.-H. | en-US |
dc.contributor.author | Mansor M. | en-US |
dc.contributor.author | Wahjuprajitno B. | en-US |
dc.contributor.author | Patel A. | en-US |
dc.contributor.author | Wittayachanyapong S. | en-US |
dc.contributor.author | Sany B.S.M. | en-US |
dc.contributor.author | Lin S.-F. | en-US |
dc.contributor.author | Dimopoulos G. | en-US |
dc.creator | Simon J.;Hsin-Yun Sun;Leong H.N.;Barez M.Y.C.;Huang P.-Y.;Talwar D.;Wang J.-H.;Mansor M.;Wahjuprajitno B.;Patel A.;Wittayachanyapong S.;Sany B.S.M.;Lin S.-F.;Dimopoulos G. | - |
dc.date.accessioned | 2020-12-29T05:33:47Z | - |
dc.date.available | 2020-12-29T05:33:47Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0933-7407 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886288504&doi=10.1111%2fmyc.12085&partnerID=40&md5=aa0fde63a7db1947bd70d6540d2832c5 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/535399 | - |
dc.description.abstract | We summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managing IC. The echinocandins have demonstrated good activity against non-albicans infections and also azole-resistant strains, both preclinically and in recent clinical trials. As well as proving efficacious, echinocandins have a favourable safety profile and are well tolerated, including among inpatient subpopulations, such as transplant recipients and those with renal or hepatic dysfunction. In addition the echinocandins generally have minimal drug-drug interactions, unlike the oral azoles, which have multiple effects on cytochrome P450-mediated drug metabolism. Echinocandins are characterised by a good safety profile, few drug-drug interactions and good susceptibilities. With the increase in potentially azole-resistant non-albicans infections, echinocandins may become the first-line treatment of choice for many patients. ? 2013 Blackwell Verlag GmbH. | - |
dc.publisher | Blackwell Publishing Ltd | - |
dc.relation.ispartof | Mycoses | - |
dc.subject.other | amphotericin B; anidulafungin; caspofungin; cytochrome P450; fluconazole; host factor; micafungin; abdominal pain; antifungal activity; antifungal susceptibility; area under the curve; Candida albicans; candidemia; critically ill patient; diarrhea; disease predisposition; drug clearance; drug efficacy; drug protein binding; drug safety; fever; fungus growth; graft recipient; hematopoietic stem cell transplantation; human; iatrogenic disease; in vitro study; infection risk; invasive candidiasis; maximum plasma concentration; minimum inhibitory concentration; nausea; phlebitis; priority journal; review; time to maximum plasma concentration; vomiting; candidaemia; critically ill; Echinocandins; Antifungal Agents; Candidiasis, Invasive; Echinocandins; Humans; World Health | - |
dc.subject.other | [SDGs]SDG3 | - |
dc.title | Echinocandins in invasive candidiasis | en_US |
dc.type | review | - |
dc.identifier.doi | 10.1111/myc.12085 | - |
dc.identifier.pmid | 23647521 | - |
dc.relation.pages | 601-609 | - |
dc.relation.journalvolume | 56 | - |
dc.relation.journalissue | 6 | - |
item.grantfulltext | none | - |
item.fulltext | no fulltext | - |
item.openairetype | review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.orcid | 0000-0003-0074-7721 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.